COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection
to severe organ damage and death. We characterized the time-dependent progression of …

Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to
optimize allocation of treatment and resources in intensive care, as clinically established risk …

Aberrant B-cell receptor/NF-κB signaling is a hallmark feature of B-cell non-Hodgkin
lymphomas, especially in diffuse large B-cell lymphoma (DLBCL). Recurrent mutations in this …

Simple Summary Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive
non-Hodgkin’s lymphoma. About two-thirds of patients are cured by the first-line (1L) standard …

COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection
to severe organ damage and death. There is an urgent need for predictive markers that can …

Objectives Dexamethasone has become the standard of care for severe coronavirus disease
2019 (COVID-19), but its virological impact is poorly understood. The objectives of this …

The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label
Phase I/II study for patients 61–80 years of age with newly diagnosed CD20 + diffuse large B-…

Post-transplant lymphoproliferative disorders (PTLDs) occur with an incidence of 0.9-2.6%
after liver transplantation [1]. PTLD is associated with high mortality: the overall survival at 1-…

Background Any inflammatory response following corneal transplantation may induce
rejection and irreversible graft failure. The purpose of this study is to analyze the anti-inflammatory …

Diffuse large-cell B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. About
30–40% of the patients will not be cured by standard Rituximab (R)-CHOP-like immune-…